This chemo-enzymatic peptide synthetic technology offers an entry into economic manufacturing processes for linear peptide drugs and small proteins. The potential of the peptiligase technology however extends far beyond linear peptides and small proteins, to areas such as macrocycles (cyclotides), antibody-drug conjugates and conjugated dual inhibitors. The enzyme does not need a specific sequence of amino acids for the recognition and does not require modifications in the sequence to make it work. Furthermore, it is highly efficient and very well scalable to kg-scale. In this poster, we’ll share several cases showing longer peptide and small protein syntheses using this technology.

Chris McGee leads the Global Business Development department at Bachem. Together with a team of specialized business development professionals, he works to provide bespoke solutions for partners developing novel peptide- and oligonucleotide-based entities. He is passionate about our contribution to the discovery and development of innovative medicines and products and maintaining an industry-leading all-around experience for our partners.  Chris has a Ph.D. in organic chemistry from the University of California, Irvine, and more than a decade of experience with Bachem.